Claris Lifesciences is currently trading at Rs. 178.10, up by 6.60 points or 3.85% from its previous closing of Rs. 171.50 on the BSE.
The scrip opened at Rs. 178.00 and has touched a high and low of Rs. 179.50 and Rs. 175.50 respectively. So far 4,840 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 292.20 on 05-Dec-2012 and a 52 week low of Rs. 142.05 on 18-Jun-2013.
The current market cap of the company is Rs. 1,136.00 crore.
The promoters holding in the company stood at 60.21% while Institutions and Non-Institutions held 24.15% and 13.79% respectively. Claris Lifesciences has completed the transfer of its Infusion business in India and Emerging Markets; to the joint venture (JV) ‘Claris-Otsuka’; with Otsuka Pharmaceutical Factory, Inc., Japan (OPF) and Mitsui & Company, Japan (Mitsui). The Infusion business includes Common Solutions, Anti-Infective, Plasma Volume Expanders and Parenteral Nutrition therapies for India and Emerging Markets.
The company has transferred two of its existing plants to the JV and will continue to hold 20% stake in the JV, while Otsuka and Mitsui will hold 60% and 20% respectively. The company has received a total cash consideration of Rs 1,050 crore as a part of the transaction from Claris-Otsuka. Claris-Otsuka is valued at Rs 1,313 crore.
Claris Lifesciences is one of the largest sterile injectables pharmaceutical companies in India. The company manufactures and markets products across various therapeutic segments including Anesthesia, Plasma Volume Expanders, Blood Products, Parenteral & Enteral Nutrition, Infusion therapy, Anti-infective and Renal Care.
| Company Name | CMP |
|---|---|
| Redington | 234.90 |
| Adani Enterprises | 2218.35 |
| Amrapali Industries | 17.53 |
| Rashi Peripheral | 455.25 |
| PDS | 301.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: